scholarly journals ROLE OF NASYA IN THE MANAGEMENT OF DYSFUNCTIONAL UTERINE BLEEDING - A REVIEW

2021 ◽  
pp. 68-71
Author(s):  
Aparna S ◽  
Maya Balakrishnan ◽  
Giby Thomas
Keyword(s):  
Central Nervous System ◽  
Direct Action ◽  
Uterine Bleeding ◽  
Nasal Passage ◽  
Entire Body ◽  
Endocrine Glands ◽  
Dysfunctional Uterine Bleeding ◽  
Menstrual Cycles ◽  
Adequate Quantity

Regular menstrual cycles with adequate quantity and duration of bleeding indicate good reproductive health, with variations in these being reflected as menorohagia, oligomenorrbea, dysmenorrbea, PCOD, infertility etc. Dysfunctional uterine bleeding is particularly common during adolescence and perimenopausal periods. It has been defined as a state of excessive uterine bleeding without clinically detectable organic, systemic and iatrogenic causes. DUB is caused by the abnormal functioning of hypothalamo – pituitary – ovarian axis. Nasya is a term applied generally when the medicine is administered through the nasal passage. It is considered as the most specific Panchakarama therapy used for the diseases of Siras (head) or Urdva jatru region, as nasal passage is regarded as the gateway to the head. In the present article the possible role of Nasya in the management of dysfunctional uterine bleeding is discussed. Nasya indirectly work on the entire body by improving the functioning of central nervous system and endocrine glands. The neurons which stimulate production of GnRH, originates from the olfactory area and GnRH is the regulator of gonadotropin hormones. The hormones of menstruation are under the control of these secreted by the pituitary. Nasya which is considered as having direct action on neuro-endocrinological system may regulate HPO axis and normalize the menstruation.

An implant of a gonadotropin releasing hormone agonist (buserelin) which suppresses ovarian function in the macaque for 3–5 months

1987 ◽  
Vol 115 (4) ◽  
pp. 521-527 ◽  
Author(s):  
H. M. Fraser ◽  
J. Sandow ◽  
H. Seidel ◽  
W. von Rechenberg
Keyword(s):  
Ovarian Function ◽  
Uterine Bleeding ◽  
Rapid Decline ◽  
Prolonged Release ◽  
Dysfunctional Uterine Bleeding ◽  
Serum Progesterone ◽  
Menstrual Cycles ◽  
Important Addition ◽  
Intact Molecule ◽  
Single Implant

Abstract. Four adult female stumptailed macaque monkeys with regular menstrual cycles and one with irregular cycles and dysfunctional uterine bleeding were treated with a single implant containing 2.6 mg of the GnRH agonist buserelin in a matrix of polylactide/glycolide copolymer (75:25). The implant was used as a cylindrical rod of 0.8 × 0.12 cm and implanted sc in the abdominal wall. The insertion of the implant was followed by a modest rise in serum concentrations of LH and FSH lasting 3–4 days before falling to basal values. The release profile of buserelin from the implant was measured in urine by a radioimmunoassay detecting the intact molecule and its major metabolites. Immunoreactive buserelin in urine was high between days 1–3 after implant after which there was a rapid decline to form a plateau between days 15–70 followed by a further gradual decline. This prolonged release of buserelin suppressed ovulation for a mean of 148 days (range 105–182 days) as indicated by absence of serum progesterone rises. Serum FSH concentrations were low for at least 75 days and during this time serum oestradiol concentrations were uniformly suppressed in all monkeys. Once the buserelin release from the implant declined serum FSH concentrations began to rise. There was a variable delay of 7–60 days before this rise in FSH was associated with stimulation of ovarian oestradiol secretion followed by rises in serum progesterone concentrations indicative of ovulation. Apart from the first menses after insertion of implant, 4 of the monkeys became amenorrhoeic for the period of anovulation. The remaining monkey had dysfunctional uterine bleeding prior to treatment and this gradually decreased before disappearing 7 weeks after implant. These results show that this buserelin implant can provide sustained release of peptide to suppress pituitary-ovarian function in the macaque for at least 3 months. Such an implant should provide an important addition to the currently available modes of administration for the clinical use of GnRH agonists.

scholarly journals The role of Sevista (ormeloxifene) in the management of dysfunctional uterine bleeding

2016 ◽  
Vol 6 (1) ◽  
pp. 219 ◽  
Author(s):  
Nikita Gandotra ◽  
Preeti Sharma ◽  
Abhinav Sharma ◽  
Syed Masuma Rizvi
Keyword(s):  
Side Effects ◽  
Outcome Measures ◽  
Medical Management ◽  
Endometrial Thickness ◽  
Hemoglobin Concentration ◽  
Uterine Bleeding ◽  
Secondary Outcome ◽  
Dysfunctional Uterine Bleeding ◽  
The Mean

Background: Dysfunctional uterine bleeding (DUB) is a common gynaecological disorder that usually ends up in hysterectomy and causes psychological and physiological stress. Medical management with hormones and NSAIDS has inherited side effects. Ormeloxifene, a selective estrogen receptor modulator, is emerging as a safe and effective agent for dysfunctional uterine bleeding. The objective of the study was to evaluate the role of ormeloxifene in medical management of dysfunctional uterine bleeding.Methods: 30 patients, on whom diagnosis of dysfunctional uterine bleeding was made, were included in the study. Patients were given ormeloxifene 60mg twice a week for 12 weeks and then once a week for 12 weeks. The primary outcome measures were menstrual blood loss (assessed by pictorial blood assessment chart score), hemoglobin concentration and endometrial thickness. The secondary outcome measures were acceptability and side effects of ormeloxifene.Results: There was a significant reduction in mean PBAC score from 316 to 52 after six months of treatment. The mean hemoglobin concentration increased significantly from 8.4 to 9.8 gms/dl with a rise of 1.4gm/dl (p <0.05). The mean pretreatment endometrial thickness was 10.8mm and it decreased significantly to 8.1mm after 6 months of treatment with ormeloxifene (p < 0.05). 76.7% of the women showed marked subjective improvement in symptoms. The most common side effect reported was amenorrhea (13.3%).Conclusions: Ormeloxifene can be considered as an effective and safe therapeutic option for the medical management of dysfunctional uterine bleeding.

Sign in / Sign up

Export Citation Format

Share Document